8-K: Shuttle Pharma Appoints Yuying Liang CFO, Director Resigns

Shuttle Pharmaceuticals Holdings, Inc. announced the appointment of Yuying Liang as Chief Financial Officer and the resignation of Sachin Pathigoda from its Board of Directors.

Summary

• Shuttle Pharmaceuticals Holdings, Inc. appointed Ms. Yuying Liang, CPA, as Chief Financial Officer on January 6, 2025.
• Mr. Chris Cooper will no longer serve as CFO but will continue in his role as Interim Chief Executive Officer.
• Ms. Liang's employment terms are set forth in an engagement letter with Yuying Liang Professional Corp. (YLPC), a Canadian corporation wholly owned by Ms. Liang.
• YLPC will receive a monthly fee of $15,000 USD plus applicable taxes for ongoing bookkeeping, accounting, and financial reporting services, and for Ms. Liang's service as CFO.
• Ms. Liang, age 35, is a certified public accountant with extensive experience, currently serving as CFO for multiple public and private companies.
• Mr. Sachin Pathigoda formally resigned from his position as a director of the Board, effective immediately, on January 8, 2026.
• Mr. Pathigoda's resignation was not due to any disagreement with the Company.
• The Board has initiated a process to identify and evaluate potential candidates to fill the vacancy created by Mr. Pathigoda's resignation.

Sentiment

Score: 5

Explanation: The filing details routine corporate governance changes, including a new CFO appointment and a director's resignation. There are no significant financial disclosures or strategic shifts that would indicate a strong positive or negative sentiment.

Positives

• Appointment of an experienced Certified Public Accountant (CPA), Yuying Liang, as Chief Financial Officer, bringing significant expertise in corporate accounting, financial reporting, and strategic guidance across multiple sectors.
• The new CFO has a strong background, overseeing consolidated financial reporting and ensuring compliance with IFRS and US GAAP for several public companies.

Negatives

• The resignation of Sachin Pathigoda from the Board of Directors creates a vacancy that the company needs to fill, potentially impacting board continuity until a successor is appointed.

Risks

• Potential for delays in identifying and appointing a suitable successor director to fill the Board vacancy, which could affect corporate governance and strategic oversight.
• Reliance on a professional corporation (YLPC) for CFO services and financial reporting, which, while common, introduces an external dependency for a critical executive function.

Future Outlook

The Board intends to appoint a successor director to fill the vacancy created by Mr. Pathigoda's resignation as soon as practicable, in accordance with the Company's bylaws and applicable law.

Management Comments

• Yuying Liang Professional Corp. will perform ongoing bookkeeping, accounting, financial reporting, and if required the provision for a CFO.
• The Company will provide all relevant information on a timely basis and any reasonable assistance required to perform the engagement.
• The sole responsibility for the accuracy and completeness of the representations in the financial information remains with the Company.

Industry Context

The appointment of an experienced external CPA firm for CFO services is a common practice among smaller public companies, particularly in the biotechnology or pharmaceutical sector, to manage financial reporting and compliance without the overhead of a full-time in-house executive. Director resignations are also a regular part of corporate governance, and the company's stated intention to seek a replacement aligns with standard practices.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Changes in key executive leadership and Board composition, which could influence investor confidence and strategic direction.
• Management: Chris Cooper's focus shifts solely to Interim CEO duties, while Yuying Liang takes on financial leadership.

Next Steps

• The Board will identify and evaluate potential candidates to fill the director vacancy created by Mr. Pathigoda's resignation.
• The Company intends to appoint a successor director as soon as practicable.

Key Dates

Recommendation

The filing details routine corporate governance changes, including a new CFO appointment and a director's resignation. There are no significant financial disclosures or strategic shifts that would warrant a strong buy or sell recommendation. The new CFO brings extensive experience, which is a positive, but the director vacancy needs to be filled. Overall, the information is neutral for immediate investment decisions, suggesting a 'hold' position while monitoring future developments.

Keywords

Shuttle Pharmaceuticals, SHPH, CFO appointment, director resignation, corporate governance, financial reporting, accounting services, Yuying Liang, Chris Cooper, Sachin Pathigoda